Researchers have devised a new way to separate cells by exposing them to sound waves as they flow through a tiny channel. Their device, about the size of a dime, could be used to detect the extremely rare tumor cells that circulate in cancer patients’ blood, helping doctors predict whether a tumor is going to spread.
A multidisciplinary team of scientists from the Univ. of California, Los Angeles and Stanford Univ. has used a naturally occurring nanoparticle called a vault to create a novel drug delivery system that could lead to advances in the treatment of cancer and HIV. Their findings could lead to cancer treatments that are more effective with smaller doses and to therapies that could potentially eradicate the HIV virus.
Two Northwestern Univ. scientists have identified a biomarker strongly associated with basal-like breast cancer, a highly aggressive carcinoma that is resistant to many types of chemotherapy. The biomarker, a protein called STAT3, provides a smart target for new therapeutics designed to treat this often deadly cancer.
An international team of scientists has shown that an antibody against the protein EphA3, found in the micro-environment of solid cancers, has anti-tumor effects. As EphA3 is present in normal organs only during embryonic development but is expressed in blood cancers and in solid tumors, this antibody-based approach may be a suitable candidate treatment for solid tumors.
Scientists at Yale Univ. have developed a novel cancer immunotherapy that rapidly grows and enhances a patient’s immune cells outside the body using carbon nanotube-polymer composites; the immune cells can then be injected back into a patient’s blood to boost the immune response or fight cancer.
By combining magnetic nanoparticles with one of the most common and effective chemotherapy drugs, Argonne National Laboratory researchers have created a way to deliver anti-cancer drugs directly into the nucleus of cancer cells. They have created nano-sized bubbles, or “micelles,” that contain magnetic nanoparticles of iron oxide and cisplatin, a conventional chemotherapy drug also known as “the penicillin of cancer.”
A smart technology which involves smuggling gold nanoparticles into brain cancer cells has proven highly effective in lab-based tests in the U.K. The technique could eventually be used to treat glioblastoma multiforme, which is the most common and aggressive brain tumor in adults, and notoriously difficult to treat.
Scientists have known for decades that cancer can be caused by genetic mutations, but more recently they have discovered that chemical modifications of a gene can also contribute to cancer. These alterations, known as epigenetic modifications, control whether a gene is turned on or off. Analyzing these modifications can provide important clues to the type of tumor a patient has, and how it will respond to different drugs.
Researchers from the University of Texas at Austin and five other institutions have created a molecule that can cause cancer cells to self-destruct by ferrying sodium and chloride ions into the cancer cells. These synthetic ion transporters confirm a two-decades-old hypothesis that could point the way to new anticancer drugs while also benefitting patients with cystic fibrosis.
The Food and Drug Administration has approved the first screening test for colon cancer that uses patient DNA to help spot potentially deadly tumors and growths. The Cologuard test from Exact Sciences detects irregular mutations in a patient's stool sample that can be an early warning sign of cancer. Patients who test positive for the mutations should undergo a colonoscopy to confirm the results.
In the developing brain, special proteins that act like molecular tugboats push or pull on growing nerve cells, or neurons, helping them navigate to their assigned places amidst the brain’s wiring. How a single protein can exert both a push and a pull force to nudge a neuron in the desired direction is a longstanding mystery that has now been solved by scientists from Dana-Farber Cancer Institute.
Melanoma is the fifth most common cancer type in the United States. A new handheld device may help diagnosis and treatment efforts for the disease. It uses lasers and sound waves and is the first that can be used directly on a patient to accurately measure how deep a melanoma tumor extends into the skin.
Brain tumors fly under the radar of the body’s defense forces by coating their cells with extra amounts of a specific protein, new research at the Univ. of Michigan shows. The findings, made in mice and rats, show the key role of a protein called galectin-1 in some of the most dangerous brain tumors, called high grade malignant gliomas. The stealth approach lets the tumors hide until it’s too late for the body to defeat them.
Sequencing the genomes of tumor cells has revealed thousands of mutations associated with cancer. One way to discover the role of these mutations is to breed a strain of mice that carry the genetic flaw—but breeding such mice is an expensive, time-consuming process. Now, Massachusetts Institute of Technology researchers have found an alternative.
It's long been known that faulty BRCA genes greatly raise the risk for breast cancer. Now scientists say a more recently identified, less common gene can do the same. Mutations in the gene can make breast cancer up to nine times more likely to develop, an international team of researchers reports in the New England Journal of Medicine.
Researchers have developed a simple and versatile method for making artificial anti-cancer molecules that mimic the properties of one of the body’s natural defense systems. The chemists have been able to produce molecules that have a similar structure to peptides which are naturally produced in the body to fight cancer and infection.
Imagine you're fighting for your life but no matter how hard you hit, your opponent won't go down. The same can be said of highly treatment-resistant cancers, such as head and neck cancer, where during radiation and chemotherapy some cancer cells repair themselves, survive and thrive. Head and neck cancer is the sixth most common cancer in the world, but the late detection and treatment resistance result in a high mortality rate.
We have long known that cancer cells monopolize large amounts of sugar. More recently, it became clear that some tumor cells are also characterized by a series of features such as mobility or unlikeliness to join in an ordered set. Researchers are calling this behavior “mesenchymal,” and they suspect it promotes metastasis.
The best way to cure most cases of cancer is to surgically remove the tumor. The Achilles heel of this approach, however, is that the surgeon may fail to extract the entire tumor, leading to a local recurrence. With a new technique based on injectable dye and infrared light, researchers in Pennsylvania have established a new strategy to help surgeons see the entire tumor in the patient, increasing the likelihood of a positive outcome.
Stop sunbathing and using indoor tanning beds, the acting U.S. surgeon general warned in a report released Tuesday that cites an alarming 200% jump in deadly melanoma cases since 1973. The report blames a generation of sun worshipping for the $8 billion spent to treat all forms of skin cancer each year.
Cancerous tumors protect themselves by tricking the immune system into accepting everything as normal, even while cancer cells are dividing and spreading. One pioneering approach to combat this effect is to use nanoparticles to jumpstart the body's ability to fight tumors. Recent combines these therapeutic nanoparticles with heat to stimulate the immune system.
A new study has shown that it is possible to predict long-term cancer risk from a chemical exposure by measuring the short-term effects of that same exposure. The findings could make it possible to develop simpler and cheaper tests to screen chemicals for their potential cancer causing risk.
The U.S. Food and Drug Administration on Wednesday approved a new cancer drug from Gilead Sciences Inc. to treat three types of blood cancer. Regulators approved the drug for patients with forms of chronic lymphocytic leukemia, follicular lymphoma and small lymphocytic lymphoma. The cancers affect an estimated 200,000 patients in the U.S., according to Gilead.
In the U.K., researchers have revealed the structure of one of the most important and complicated proteins in cell division, the anaphase-promoting complex. Electron microscopy and software has produced images of the gigantic protein in unprecedented detail and could transform scientists' understanding of exactly how cells copy their chromosomes and divide. It could also reveal binding sites for future cancer drugs.
Yale School of Medicine and Yale Cancer Center researchers have uncovered a genetic vulnerability of cancer cells that express telomerase and showed that telomerase-expressing cells depend upon a gene named p21 for their survival. Authors found that simultaneous inhibition of both telomerase and p21 inhibited tumor growth in mice.